Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | TUXEDO-1: trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastases

Gaia Griguolo • 3 May 2022
ESMO Breast 2022
Breast Cancer Antibodies Trastuzumab deruxtecan
TUXEDO-1

Gaia Griguolo, MD, University of Padova, Padova, Italy, discusses the significance of the Phase II TUXEDO-1 trial (NCT04752059) investigating trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastases. A response rate of over 70% was demonstrated, as well as progression-free survival (PFS) rate of over 1 year. Active systemic agents for the treatment of this patient population could enable for the delay of whole-brain radiotherapy and ultimately improve quality of life, in addition to overall survival (OS). This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

More from Gaia Griguolo

Characterizing genetic mutations with NGS in breast cancer brain metastases
2:21
Characterizing genetic mutations with NGS in breast cancer brain metastases
Gaia Griguolo • 13 Dec 2024
SABCS 2024 Highlights: PATINA in HR+/HER2+ breast cancer
2:09
SABCS 2024 Highlights: PATINA in HR+/HER2+ breast cancer
Gaia Griguolo • 13 Dec 2024
Immune microenvironment evolution in breast cancer brain metastases
2:13
Immune microenvironment evolution in breast cancer brain metastases
Gaia Griguolo • 5 Jun 2024
Genomic profiling of HR+/HER2- breast cancer and brain metastases
3:10
Genomic profiling of HR+/HER2- breast cancer and brain metastases
Gaia Griguolo • 5 Jun 2024

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals